{"name":"Adamas Pharmaceuticals, Inc.","slug":"adamas-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ADS-5102","genericName":"ADS-5102","slug":"ads-5102","indication":"Levodopa-induced dyskinesia in Parkinson's disease patients","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ADS-8902","genericName":"ADS-8902","slug":"ads-8902","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"ADS-5102","genericName":"ADS-5102","slug":"ads-5102","phase":"phase_3","mechanism":"ADS-5102 is an extended-release formulation of amantadine that provides sustained dopaminergic and anti-glutamatergic activity to reduce involuntary movements.","indications":["Levodopa-induced dyskinesia in Parkinson's disease patients"],"catalyst":""},{"name":"ADS-8902","genericName":"ADS-8902","slug":"ads-8902","phase":"phase_2","mechanism":"ADAMS-8902's mechanism of action is currently under investigation and not fully characterized.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQTDVTMUpoNGJqcXZPLUlCQ2ZVTGx1WE50ZkZoOHNRODByZktYLXVOa0ZWZFhMZ0dsc3JBWU1NSWxNejh2UG81NV92TlVLQUlyMmNPa3VfajZIOVZBM2pFaXZMR0ZSRkprY0pkWVRxRFNSbzRpNEctTnpPd1MyWVFaeWkzWGJfQTRxcHRUY3ZUMFN6QWVBRHh1TmEtaDAtVktFNFh4Rw?oc=5","date":"2026-04-01","type":"pipeline","source":"Meyka","summary":"ADMS Adamas Pharma NASDAQ Apr 2026 Pre-Mkt $8.22: Oversold bounce 10.7% upside - Meyka","headline":"ADMS Adamas Pharma NASDAQ Apr 2026 Pre-Mkt $8.22: Oversold bounce 10.7% upside","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPVjNDREFRLUZhcURYV2xDX2xlc3JQZEFXRkZZZHB1S2U4T2phb1FGTUtGT1VXVmdCUVhGTUhzQXJOQUZmZGFrQ05OV2I1NjJzcUdBRk1uT0kwWV8zYTZfUFNEUmxLaFVfOTR1U1Q3NERpbkVfbWp3NkhOa0hMYzBBVmRFQ3pLZGlsZ1JSTlR3VFJCd3RPOWJJZw?oc=5","date":"2025-06-16","type":"deal","source":"The Business Journals","summary":"Supernus strikes deal to buy Sage Therapeutics - The Business Journals","headline":"Supernus strikes deal to buy Sage Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE9oMlBxSjNGQldWQi0wWmpXM3lmQmx4dmNnQXFha0FYdWNIbVo4d2VhU01iYVhOeEZWblBvM2FEbHNmb0E0YnhaV0JDNklJTGg0UDh2RTZYUlNfd0tHRHBGSm5vaXZZWjFGNmNiTFZ4SEhKbWFncDg0?oc=5","date":"2025-06-11","type":"pipeline","source":"Market.us","summary":"Tardive Dyskinesia Treatment Market Size, Share | CAGR Of 6.3% - Market.us","headline":"Tardive Dyskinesia Treatment Market Size, Share | CAGR Of 6.3%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNa1JDUWVSUzV0ZEJTemdvbkZPd29SRkQxdVJ4Ny1xWWx5QUtZNkR1OUlUcVpzSXVhZFhZczFOX21LMFJTNEVlMERrT0pQb0V0M2JLaG5aMXk0VURNbWladFpaZ0psaGRERnY1SExsZGlESDVyZUsxRDBJWE5vQ3Z3a0VnUU1JMnptdUZscU1yVQ?oc=5","date":"2024-02-07","type":"trial","source":"Frontiers","summary":") Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease - Frontiers","headline":") Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPV0VTRFlyY1o2YjcwNjRwOTNReDB1b0ZOS0F2ZTR0RVpLNU9mRy1oRXRZdjNVNVRCeDF3SFRaSHFVT0VPWnhEZlNUdVltLW1VU2hTRllOMXR3YmFuYVFObElKcDVYZDhGMWVtQ09xVEFHaS1XamtuTUdvb3BfcHlwTG5XcEs0SzBfeDFNSU41cjYwOHlFUHpna0lpdUNfOEJ2?oc=5","date":"2021-11-24","type":"pipeline","source":"Yahoo Finance","summary":"Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals - Yahoo Finance","headline":"Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxQc0F1cUQ2TG1yQmZ4dHZHS2kxdUR0b1pUd0JzS3BadTFoU2x4YldGUktzMU5iSjFnOVhXdElac0RKbUdnYk9UREl0ZU9tMEZkSDFjQ3AyVDNGbTBZZlZMeER4cG1PNEJFTmVaTDFaaHdoTHBCNUlwcHJ4dm4xUG9TRTJzdzFjYnNnU3hfUFYyeFk3RExJZC1ZVHNHd1dFYTdVcnZuWG1mN0lneHA3V3VYaWphYU9iMm5tT3I4V3Zjb3pIOTU3Y3JJUkREVWhvbEQ0TTBZNHA0RmlhQQ?oc=5","date":"2021-10-11","type":"deal","source":"Reuters","summary":"Supernus bolsters Parkinson's portfolio with $400 mln deal for Adamas Pharma - Reuters","headline":"Supernus bolsters Parkinson's portfolio with $400 mln deal for Adamas Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQVENaUWF6S2pudXNrM05KLTVvVjNYUTlyWDAta0hmOHQ5aGp4SWQyS0dfYVBCVExCY0VFRm50bGlEZkVzWHdJV0RTM0dmdVZRR3d0a016blNxaVVrMXg4Nk1oWVY4R3B3WWI2Y0t5TlZIaEtOOUZBOUFIeXV4N1Uxc3VXalZlRG9NQVh4ZDgtU2x0RVcweFB5NllTMEl0UQ?oc=5","date":"2021-10-11","type":"deal","source":"Contract Pharma","summary":"Supernus to Acquire Adamas Pharmaceuticals for $400M - Contract Pharma","headline":"Supernus to Acquire Adamas Pharmaceuticals for $400M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNbmFKdGRzZ0xnYzU0LTB4cmZid1Jla1B4THVMMXlOXzFZUTNnWlF1aGJ2d2YzZWl0THFza29POFQxZm9acDVBMG1CYlQwdHJ4Q2NQRHZ5aE0tWktuc0Y3Q1pZLV9XOTRpV2xpTzNEbV9DV1ZDazI1TDdMQ3dtZnMxT3lMWGZydw?oc=5","date":"2021-10-11","type":"deal","source":"Barron's","summary":"Flexion and Adamas Are Being Acquired. Both Stocks Are Soaring. - Barron's","headline":"Flexion and Adamas Are Being Acquired. Both Stocks Are Soaring. - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPTllmdThFRUgxQllRdHN0LTJLR3ZUd3J5NUdXTmt5Ym43aXl6bUxUZC1ETHAyLWZuX2JpMTQ3UlBxelM4d2xmbHJYVGtub0tfM0VtS3VJRXlFOHlOY2ZjLWF0eXM3RUZYSHozZnVGR0JiaXktY2dfYmNYbi1SQ0Ztc2tPX3I1N2UxN3FFb3VkLVo?oc=5","date":"2021-02-02","type":"regulatory","source":"Medical Professionals Reference","summary":"Gocovri Approved to Treat Off Episodes in Parkinson Disease - Medical Professionals Reference","headline":"Gocovri Approved to Treat Off Episodes in Parkinson Disease","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPUEwtZjlMdTdyeElfQnJoRVdGRTFBNUQ2Y2czNW9WQ3VIbmFTcFprRXhXdWNYQVlTTUVBYWstUWNIYkZxa3liWHRZZ3ZBdWc2Z0xJM0RzbjhXbnpSQ3JDWjVqS05JMno4Zi02dlF0WmZyVkYyUFVLQVNaN3oxUFV1alFLSHBPQVRobS1sVXZqSHVzQnJ3em9YVWFFVnN1clp2SDBHWWpKeGQ1NHNSV0R4bHpWazQya3ZhbXk4VGNoRXRhQQ?oc=5","date":"2020-09-01","type":"pipeline","source":"GlobeNewswire","summary":"Adamas Appoints Anna Richo to Board of Directors - GlobeNewswire","headline":"Adamas Appoints Anna Richo to Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPVGtSeG5WSVhmTXRjSlpIR240Z0gzdGxxODYwWHktTkRYNDc3ZUpOb2FfUUZKeW53RTZUSW5RRVFfYUVmcElYbGpsaGlhMnI3QmplYUUtMzE0UHptRDdXbTFxaHRSUTc5bGloSi1fMU42NElWeW54N1NtN2pTbk5GSDk3QnhGWjFFS1liNktLekh2MDZtcWR4VkNsU2w0YmFaZndHMVlXbWR3WEd4WHZhNWVCZUZpbjhBckEzaV9xdVdpTTZ5ZTRoTXBvQi1jNXBOSUhmMGFtQUY3U0NYbGc?oc=5","date":"2017-08-31","type":"patent","source":"MarketWatch","summary":"Adamas Pharma says its new Parkinson’s drug isn’t just a more expensive, long-acting version of generic - MarketWatch","headline":"Adamas Pharma says its new Parkinson’s drug isn’t just a more expensive, long-acting version of generic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPeHFZQ05OSERQSS1VRFIxM0ZqTk9TdC00X3NlRWF3YkRLUXo0YmZuYUtqeEM3cW9ULVBHcHRueEpvbktBTnBka0lWelpGRG1YaDlLS3FhWkFwOTBDNEo0VGVaSFRRMU1UUllzMl9vQVMwYzlEdk9SMWNIX29LZ0hhdF9GcTV2bUJGb2FKUA?oc=5","date":"2017-08-25","type":"regulatory","source":"BioPharma Dive","summary":"Adamas Parkinson’s drug gains FDA approval - BioPharma Dive","headline":"Adamas Parkinson’s drug gains FDA approval","sentiment":"positive"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}